Pharmaceuticals
Kintor Pharmaceutical Announces Preliminary Results from the Proxalutamide's Clinical Trial
SUZHOU, China, Dec. 11, 2020 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX: 9939) is pleased to update the preliminary analysis of the Proxalutamide's clinical trial for COVID-19. Proxalutamide is a new androgen receptor (AR) antagonist developed in by Kintor Pharmaceutical and is currentl...
2020-12-11 19:44
9374
Innovent Announces First Patient Dosed in Phase 2 Pivotal Trial of IBI310 (CTLA-4) combined with TYVYT® (sintilimab injection) for the treatment of second-line or above Advanced Cervical Cancer
SAN FRANCISCO and SUZHOU, China, Dec. 11, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...
2020-12-11 09:02
7371
Antengene Announces Acceptance of IND Application in China for a Phase 3 Clinical Trial of ATG-010 (Selinexor) in Combination with Bortezomib and Dexamethasone (SVd) for the Treatment of rrMM
SHANGHAI and HONG KONG, Dec. 11, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncol...
2020-12-11 08:00
5073
European Union Intellectual Property Office Revokes Counterfeiter's Fake AQUAGOLD® Design Registration and Orders Payment to Aquavit of All Legal Fees and Costs
NEW YORK, Dec. 11, 2020 /PRNewswire/ -- Aquavit Pharmaceuticals, Inc. ("Aquavit") received a decision from the European Union Intellectual Property Office (EUIPO) today that it has revoked the counterfeiter U-BioMed's falsely registered AQUAGOLD® design, originally created and owned by Aquavit. ...
2020-12-11 03:10
2934
INOVIO and Advaccine Announce First Dosing of Subject in Phase 2 Clinical Trial for COVID-19 DNA Vaccine Candidate INO-4800 in China
PLYMOUTH MEETING, Pa. and SUZHOU, China, Dec. 10, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, and Advaccine Biopharmaceuticals Suzhou Co., Ltd. ("...
2020-12-10 21:00
5496
Bill and Melinda Gates call for collaboration, continued innovation to overcome challenges of delivering COVID-19 scientific breakthroughs to the world
Gates Foundation pledges additional $250 million to accelerate development and equitable distribution of COVID-19 tests, treatments, and vaccines to end the pandemic SEATTLE, Dec. 10, 2020 /PRNewswire/ -- The Bill & Melinda Gates Foundation today announced it will commit an additional$250 millio...
2020-12-10 13:01
2135
Stellar Results from Kintor's GT90001 and Opdivo Combo Therapy in the Second-line Treatment of Advanced Liver Cancer: ORR Reached up to 40%
SHANGHAI, Dec. 10, 2020 /PRNewswire/ -- On December 9, 2020, Kintor Pharmaceutical Limited (HKEx: 9939) is pleased to announce that the Group has collected positive data in phase II clinical trials of combination therapy of ALK-1 (GT90001) antibody and PD-1 (Nivolumab or Opdivo) antibody for the ...
2020-12-10 12:14
2629
Ascentage Pharma Announces Updates on the Clinical Development of APG-2575, including an ORR of 70% in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
SUZHOU, China and ROCKVILLE, MD, Dec. 10, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced updates on the clinical devel...
2020-12-10 09:03
2080
CStone's Partner Blueprint Medicines Announces U.S. FDA Approval of GAVRETO (pralsetinib) for the Treatment of Patients with Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancer
SUZHOU, China, Dec. 10, 2020 /PRNewswire/ -- The partner of CStone Pharmaceuticals ("CStone", HKEX: 2616), Blueprint Medicines, announced on December 1st that the U.S. Food and Drug Administration (FDA) has approved GAVRETO™ (pralsetinib) for the treatment of patients with RET-altered thyroid can...
2020-12-10 08:30
3972
PharmAbcine presents the latest data of the ongoing Phase Ib mTNBC trial at SABCS 2020
DAEJEON, South Korea, Dec. 9, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of fully human antibody therapeutics, announced today the presentation of the latest interim data from its ongoing phase Ib combination trial of oli...
2020-12-09 23:00
1477
INOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Anal Dysplasia Caused by HPV-16/18
PLYMOUTH MEETING, Pa., Dec. 9, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer and diseases associated with HPV, today announced positive Phase 2 efficacy ...
2020-12-09 21:00
4127
Zelgen Selects Industry's First Automated, End-to-End Drug Safety System
Rapidly growing biopharma selects ArisGlobal's LifeSphere® MultiVigilance 10, benefits from industry's first cognitive automation and AI-enabled safety system, a game-changer for patient safety MIAMI, Dec. 9, 2020 /PRNewswire/ -- ArisGlobal, the leading provider of life sciences software that au...
2020-12-09 05:07
1982
Henlius Adalimumab Biosimilar Approved by NMPA
SHANGHAI, Dec. 8, 2020 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the adalimumab biosimilar HLX03, developed and manufactured by the Company independently, has been approved by the National Medical Products Administration (NMPA) for the treatment of rheumatoid arthrit...
2020-12-08 21:00
2872
Novaliq Announces First Patient Randomized in the Phase 3 trial ESSENCE-2 of CyclASol® Topical Ophthalmic Solution for the Treatment of Dry Eye Disease
- ESSENCE-2 is the second registration trial to complete the clinical development of CyclASol® as agreed with U.S. Food and Drug Administration (FDA) - Designed to replicate efficacy demonstrated in previous phase 2/3 ESSENCE-1 trial - Topline data expected in 2nd half 2021 HEIDELBERG, Germany,...
2020-12-08 21:00
1304
Nuance Pharma Closes Series D Financing
SHANGHAI, Dec. 8, 2020 /PRNewswire/ -- Nuance Pharma, a biopharmaceutical company engaged in creating value throughChina's specialty pharmaceutical markets with an established focus on iron deficiency, pain management and respiratory, today announced that it has successfully closed its Series D ...
2020-12-08 17:34
3151
Nuance Pharma Closes Series D Financing
SHANGHAI, Dec. 8, 2020 /PRNewswire/ -- Nuance Pharma, a biopharmaceutical company engaged in creating value throughChina's specialty pharmaceutical markets with an established focus on iron deficiency, pain management and respiratory, today announced that it has successfully closed its Series D ...
2020-12-08 16:00
4544
Ascentage Pharma Announces Positive Data from Pivotal Phase II Studies of HQP1351 (Olverembatinib) in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) at 2020 American Society of Hematology (ASH) Annual Meeting
SUZHOU, China, and ROCKVILLE, MD, Dec. 8, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today reported positive data from two pivotal...
2020-12-08 08:16
2424
Aizon Lauded by Frost & Sullivan for Its AI-powered Platform that Enables Pharma Companies to Achieve Smart and Continuous Manufacturing
Aizon accelerates pharma manufacturing by bolstering the client's currently deployed technology with AI and ML capabilities to boost production performance SANTA CLARA, Calif., Dec. 7, 2020 /PRNewswire/ -- Based on its recent analysis of the North American artificial intelligence (AI) market for ...
2020-12-08 01:57
1529
PostEra enters a multi-year strategic partnership with Pfizer Inc. to advance machine learning for Drug Discovery
SAN FRANCISCO, Dec. 7, 2020 /PRNewswire/ -- PostEra, a biotechnology company specializing in machine learning solutions for preclinical drug discovery, today announced a strategic partnership with Pfizer Inc. (NYSE: PFE) with the goal of accelerating small molecule drug discovery by developing a ...
2020-12-07 22:37
4004
Through Strategic Collaboration with GenScript ProBio, Initium Therapeutics Plans to Utilize GenScript ProBio's Berkeley Lights Beacon Platform to Expand Their Antibody Drug Pipeline
NANJING, China, Dec. 7, 2020 /PRNewswire/ -- On December 7, 2020, GenScript ProBio and Initium Therapeutics announced that Initium Therapeutics has launched a single B-cell based antibody development platform through collaboration with GenScript ProBio. Initium Therapeutics is a US biotechnology ...
2020-12-07 22:00
1588
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
7722
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7116